Shares of Cabaletta Bio, Inc. (NASDAQ:CABA – Get Free Report) have been given an average recommendation of “Buy” by the ten brokerages that are covering the stock, MarketBeat reports. Ten investment analysts have rated the stock with a buy recommendation. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $28.10.
Several research analysts recently issued reports on CABA shares. UBS Group started coverage on shares of Cabaletta Bio in a research report on Thursday. They set a “buy” rating and a $10.00 price target on the stock. HC Wainwright reiterated a “buy” rating and set a $25.00 price target on shares of Cabaletta Bio in a research report on Tuesday, September 17th. Wells Fargo & Company cut their target price on shares of Cabaletta Bio from $35.00 to $20.00 and set an “overweight” rating on the stock in a research report on Monday, August 12th. Evercore ISI cut their target price on shares of Cabaletta Bio from $25.00 to $15.00 and set an “outperform” rating on the stock in a research report on Monday, August 12th. Finally, Stifel Nicolaus restated a “buy” rating and set a $32.00 target price on shares of Cabaletta Bio in a research report on Monday, June 17th.
Check Out Our Latest Research Report on Cabaletta Bio
Institutional Investors Weigh In On Cabaletta Bio
Cabaletta Bio Trading Up 6.6 %
CABA opened at $4.21 on Thursday. The company has a fifty day simple moving average of $4.75 and a 200 day simple moving average of $8.84. The firm has a market cap of $205.66 million, a price-to-earnings ratio of -2.22 and a beta of 2.39. Cabaletta Bio has a twelve month low of $3.47 and a twelve month high of $26.35.
Cabaletta Bio (NASDAQ:CABA – Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.01). On average, analysts forecast that Cabaletta Bio will post -2.28 earnings per share for the current fiscal year.
Cabaletta Bio Company Profile
Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.
Featured Stories
- Five stocks we like better than Cabaletta Bio
- What Investors Need to Know About Upcoming IPOs
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
- Which Wall Street Analysts are the Most Accurate?
- China’s EV Rally: Should Investors Chase, Avoid, or Buy the Dip?
- How to Use the MarketBeat Dividend Calculator
- MarketBeat Week in Review – 10/7 – 10/11
Receive News & Ratings for Cabaletta Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cabaletta Bio and related companies with MarketBeat.com's FREE daily email newsletter.